Logo

Kite’s Yescarta Receives EC’s Approval as 2L Treatment of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Share this

Kite’s Yescarta Receives EC’s Approval as 2L Treatment of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Shots:

  • The EC has granted approval to Yescarta for adult patients with DLBCL and HGBL who relapse within 12mos. from completion or are refractory to 1L chemoimmunotherapy
  • The approval was based on the P-III (ZUMA-7) study evaluating Yescarta vs SoC in 359 adult patients with r/r LBCL within 12mos. at 77 centers. The study showed a ≥4-fold improvement in 1EPs of EFS (8.3mos. vs 2.0mos.) at a median follow-up of 2yrs. & had a safety profile that was consistent with prior studies
  • Additionally, a 2.5-fold increase in patients who were alive @2yrs. without disease progression or need for additional treatment (41% v 16%). The results were consistent in patient subgroups, grade ≥3 CRS & neurologic events (6% & 21%) with no grade 5 CRS or neurologic events

Ref: Businesswire | Image: Kite

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions